Markers of insulin resistance associated with non-alcoholic fatty liver disease in non-diabetic population.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
22 Nov 2023
Historique:
received: 01 08 2023
accepted: 11 11 2023
medline: 24 11 2023
pubmed: 23 11 2023
entrez: 22 11 2023
Statut: epublish

Résumé

Insulin resistance (IR) plays an important role in the development of non-alcoholic fatty liver disease (NAFLD). IR markers are divided into two types: (1) insulin-based IR marker, homeostatic model assessment of IR (HOMA-IR); and (2) non-insulin-based IR markers, such as triglyceride-glucose (TyG) index, TyG index with body mass index (TyG-BMI), triglyceride/high-density lipoprotein cholesterol ratio (TG/HDL-c), and metabolic score for IR (METS-IR). The non-insulin-based IR markers are often associated with lipids. The aim of this study was to analyse the association between IR markers and NAFLD in non-diabetic population. Baseline data of NAFLD and non-NAFLD groups were compared. Logistic regression was used to evaluate the relationship between five IR markers and NAFLD risk. The odds ratios (ORs) and 95% confidence intervals (CIs) of IR markers were calculated. Receiver operating characteristic (ROC) curves and area under the curve (AUC) were used to evaluate the ability of different IR markers to detect NAFLD. Subgroup analyses were performed in obese and non-obese subgroups. This study found a positive correlation between NAFLD risk and elevation in five IR markers (HOMA-IR, TyG, TyG-BMI, TG/HDL-c, and METS-IR). In non-obese subjects, the AUC of TyG-BMI was larger than that of the other four IR markers to detect NAFLD. The AUC of HOMA-IR was larger than that of the other four IR markers to detect NAFLD in obese subjects. In non-diabetic population, the five IR markers are associated with the risk of NAFLD, including non-obese and obese NAFLD. TyG-BMI and HOMA-IR can be used to detect non-obese and obese NAFLD, respectively, with better detection ability compared with the other IR markers.

Identifiants

pubmed: 37993481
doi: 10.1038/s41598-023-47269-4
pii: 10.1038/s41598-023-47269-4
pmc: PMC10665395
doi:

Substances chimiques

Blood Glucose 0
Biomarkers 0
Glucose IY9XDZ35W2
Triglycerides 0
Cholesterol, HDL 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

20470

Subventions

Organisme : Guangzhou Municipal Science and Technology Project
ID : 202102080649

Informations de copyright

© 2023. The Author(s).

Références

Endocr Rev. 2019 Oct 1;40(5):1367-1393
pubmed: 31098621
Hepatobiliary Surg Nutr. 2021 Dec;10(6):811-824
pubmed: 35004947
J Intern Med. 2020 Jul;288(1):139-151
pubmed: 32319718
Dis Markers. 2022 Feb 23;2022:4930355
pubmed: 35251371
Diabetes Metab Syndr Obes. 2023 Jun 07;16:1685-1696
pubmed: 37309507
Hepatology. 2019 Aug;70(2):711-724
pubmed: 30556145
Biomedicines. 2021 Dec 22;10(1):
pubmed: 35052690
Front Endocrinol (Lausanne). 2023 Jul 17;14:1224967
pubmed: 37534205
Hepatology. 2010 May;51(5):1593-602
pubmed: 20222092
Front Endocrinol (Lausanne). 2023 Jan 19;14:1083032
pubmed: 36742412
Hepatology. 2020 May;71(5):1851-1864
pubmed: 32012320
Lancet. 2021 Jun 5;397(10290):2212-2224
pubmed: 33894145
Cardiovasc Diabetol. 2022 Oct 14;21(1):210
pubmed: 36242001
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
Hepatol Int. 2020 Dec;14(6):889-919
pubmed: 33006093
Medicine (Baltimore). 2017 Jun;96(22):e7041
pubmed: 28562560
Intern Med. 2023 May 24;:
pubmed: 37225482
Lancet Gastroenterol Hepatol. 2019 May;4(5):389-398
pubmed: 30902670
Arch Endocrinol Metab. 2023 Jan 18;67(1):119-125
pubmed: 36468919
Clin Mol Hepatol. 2022 Oct;28(4):790-801
pubmed: 35545437
Aliment Pharmacol Ther. 2014 Nov;40(10):1209-22
pubmed: 25267215
Am J Physiol. 1979 Sep;237(3):E214-23
pubmed: 382871
Clin Gastroenterol Hepatol. 2017 Apr;15(4):474-485
pubmed: 27581063
PLoS One. 2021 Aug 25;16(8):e0255535
pubmed: 34432804
BMC Endocr Disord. 2022 Apr 15;22(1):101
pubmed: 35428219
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Hepatol Commun. 2017 Nov 30;2(1):48-57
pubmed: 29404512

Auteurs

Pei Zeng (P)

Guangzhou Cadre Health Management Center, Guangzhou, 510000, China. 454300573@qq.com.

Xiangsheng Cai (X)

Guangzhou Cadre Health Management Center, Guangzhou, 510000, China.

Xiaozhou Yu (X)

School of Public Health, Sun Yat-Sen University, Guangzhou, 510000, China.

Linjing Gong (L)

Guangzhou Cadre Health Management Center, Guangzhou, 510000, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH